menu
    • menu
    [{"orgOrder":0,"company":"Kevin Winthrop","sponsor":"National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orc-13661","moa":"Potassium channel","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Kevin Winthrop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at","highestDevelopmentStatusID":"8","companyTruncated":"Kevin Winthrop \/ National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at"}]

    Find Clinical Drug Pipeline Developments & Deals for Orc-13661

    Menu

    Orc-13661

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kevin Winthrop

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Kevin Winthrop

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orc-13661

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

                            Details : Orc-13661 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ototoxicity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : Orc-13661

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Deafness and Other Communication Disorders | National Center for Advancing Translational Sciences | Oricula Therapeutics | University of Washington | National Jewish Health | Mayo Clinic | University of Texas Health Science Center at

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth